Infectious embryofetopathy

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:232035
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Infectious embryofetopathy refers to a group of congenital conditions caused by maternal infections transmitted to the developing embryo or fetus during pregnancy. These infections can occur at various stages of gestation and may lead to a wide spectrum of structural malformations, organ damage, and functional impairments depending on the timing of infection and the causative pathogen. The term encompasses damage caused by well-known teratogenic infectious agents including, but not limited to, rubella virus, cytomegalovirus (CMV), Toxoplasma gondii, herpes simplex virus, varicella-zoster virus, Zika virus, and Treponema pallidum (syphilis) — historically grouped under the acronym TORCH infections. The body systems most commonly affected include the central nervous system (microcephaly, intracranial calcifications, intellectual disability, sensorineural hearing loss), the eyes (chorioretinitis, cataracts, microphthalmos), the cardiovascular system (congenital heart defects), and the liver and spleen (hepatosplenomegaly, jaundice). Growth restriction, thrombocytopenia with petechiae, and skeletal abnormalities may also be present. The severity of the embryofetopathy depends on the gestational age at the time of infection, with first-trimester infections generally causing the most severe structural malformations. Treatment is largely supportive and depends on the specific organ systems involved. Some infections, such as congenital toxoplasmosis and congenital syphilis, can be treated with antimicrobial therapy during pregnancy or in the neonatal period to reduce disease severity. Antiviral agents (e.g., ganciclovir for symptomatic congenital CMV) may be used in select cases. Prevention through maternal vaccination (e.g., rubella, varicella), screening programs, and hygiene measures remains the most effective strategy. Long-term multidisciplinary follow-up involving neurology, ophthalmology, audiology, and developmental specialists is typically required.

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Infectious embryofetopathy.

View clinical trials →

No actively recruiting trials found for Infectious embryofetopathy at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Infectious embryofetopathy community →

No specialists are currently listed for Infectious embryofetopathy.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Infectious embryofetopathy.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Infectious embryofetopathyForum →

No community posts yet. Be the first to share your experience with Infectious embryofetopathy.

Start the conversation →

Latest news about Infectious embryofetopathy

No recent news articles for Infectious embryofetopathy.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Infectious embryofetopathy

What is Infectious embryofetopathy?

Infectious embryofetopathy refers to a group of congenital conditions caused by maternal infections transmitted to the developing embryo or fetus during pregnancy. These infections can occur at various stages of gestation and may lead to a wide spectrum of structural malformations, organ damage, and functional impairments depending on the timing of infection and the causative pathogen. The term encompasses damage caused by well-known teratogenic infectious agents including, but not limited to, rubella virus, cytomegalovirus (CMV), Toxoplasma gondii, herpes simplex virus, varicella-zoster virus

At what age does Infectious embryofetopathy typically begin?

Typical onset of Infectious embryofetopathy is neonatal. Age of onset can vary across affected individuals.